Reasons driving choice and clinical course of patients with CNS WHO grade 3 IDH mutant glioma receiving vorasidenib after surgery: a pilot experience

Key Points

• Vorasicenib treatment led to notable changes in clinical course for glioma patients after surgery.
• IDH mutant glioma patients showed varying responses to vorasidenib, impacting long-term management.
• Observational analysis across clinical data reveals significant treatment choice drivers in CNS glioma contexts.
• Supports the need for personalized treatment approaches in managing IDH mutant glioma cases.